Biogen was hoping that the efficacy of the drug would be amped up for the 6-mg dose, which had not yet matured in March, with the better tox profile allowing for a safer drug. The spokesman for Biogen noted that the worsening ARIA-E rate among non-ApoE4 carriers was the result of one case.
"When we start breaking down the treatment groups, we are getting into very small sample sizes, and those data reflect one additional patient in the additional 6 months we are reporting," he noted.
Biogen's two Phase III's have already begun, with investigators recruiting 1,350 patients for a 5-year study, according to ClinicalTrials.gov. Analysts, though, expect to see data around 2018 that would help determine where Biogen is headed with this drug.
There are two ongoing ph III trials with Aducanumab. Based on the large number enrolled and the start date of the trials we'd have heard of serious toxicity issues by now.
The Engage and Emerge trials are being done on a global scale. Qualified patients will participate in one or the other, but, not both. Go to this link if you have a family member you'd like to get into the trial. https://www.aducanumabclinicaltrials.com/about-these-studies
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE) Study Start: August 2015 178 locations
https://clinicaltrials.gov/ct2/show/NCT02477800?term=aducanumab&rank=5&submit_fld_opt=
Estimated Enrollment: 1350
Study Start Date: August 2015
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE) Study Start: September 2015 173 locations
https://clinicaltrials.gov/ct2/show/NCT02484547?term=aducanumab&rank=4&submit_fld_opt=
Estimated Enrollment: 1350
Study Start Date: September 2015
Estimated Study Completion Date: February 2022
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
It's going to be a few years before we get results on efficacy from these ph III's.
Ph I side effects
Amyloid-related imaging abnormalities (ARIAs) were monitored with four MRI scans, read both locally and by a central reader at an imaging CRO. Side effects included headache, diarrhea, and dizziness. They were mild or moderate, some possibly related to the study drug but not to the dose.
Aducanumab | ALZFORUM
http://www.alzforum.org/therapeutics/aducanumab
There is no ph II listed on clinical trials.gov
Only ph I and ph III...
I don't hold long or short here... just watching Alzheimer's trials with hope that one of them come through with some meaningful therapies.
In Reply to 'Cbdpotential'
http://www.fiercebiotech.com/r-d/updated-a-setback-biogen-s-mid-range-dose-of-aducanumab-flops-alzheimer-s-study
To follow KarinCA, click here then click "Follow This Member" under my photo.
Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Recent BIIB News
- Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain • PR Newswire (US) • 08/22/2024 09:10:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/16/2024 10:40:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:30:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 08:11:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:55:02 AM
- Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen • PR Newswire (US) • 07/31/2024 01:00:00 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC • GlobeNewswire Inc. • 07/30/2024 09:15:17 PM
- New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Alzheimer's Association International Conference (AAIC) 20 • PR Newswire (US) • 07/30/2024 09:00:00 PM
- Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union • GlobeNewswire Inc. • 07/26/2024 11:20:38 AM
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor • Business Wire • 07/24/2024 10:30:00 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB • PR Newswire (US) • 07/17/2024 09:45:00 AM
- Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB • PR Newswire (US) • 07/16/2024 08:00:00 AM
- Biogen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BIIB • PR Newswire (US) • 07/12/2024 09:45:00 AM
- July 22, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against BIIB • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Biogen Completes Acquisition of Human Immunology Biosciences • GlobeNewswire Inc. • 07/02/2024 01:16:51 PM
- Nike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera for $2.3 Billion, and More News • IH Market News • 06/28/2024 10:50:25 AM
- The Gross Law Firm Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 06/28/2024 09:45:00 AM
- “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China • GlobeNewswire Inc. • 06/27/2024 11:39:36 PM
- Class Action Filed Against Biogen Inc. (BIIB) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Shareholders of Biogen Inc. Should Contact The Gross Law Firm Before July 22, 2024 to Discuss Your Rights - BIIB • PR Newswire (US) • 06/17/2024 09:45:00 AM
- Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/10/2024 09:45:00 AM
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease • GlobeNewswire Inc. • 06/09/2024 11:37:43 PM
- FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease • PR Newswire (US) • 06/09/2024 11:30:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM